Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/5/2025 | $14.00 | Buy | H.C. Wainwright |
3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)
10-Q - Phio Pharmaceuticals Corp. (0001533040) (Filer)
H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00
HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial designed to evaluate the safety and tolerability of intratumoral (IT) PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 m
Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Mr. Bitterman will also host one-on-one meetings with investors at the conferen
Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep
Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May
Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)
SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)